BioWorld

Oct. 5, 2006

Plexxikon Enters Roche Deal On B-Raf Inhibitors For $706M

Earlier this week, Plexxikon Inc.'s president Kathleen Sereda Glaub told BioWorld Today that the company was in "active partnering mode." (BioWorld Today) Read More

Genentech, CGI In Potential $500M Kinase-Focused Deal

Killing Bacterial Gang Of Four Can Divide, Conquer Biofilms

HGS Updates Pipeline, Unveils Albuferon Phase III HCV Plans

Capitalizing On Stock Boost, Acorda Raises $32M Privately

Clinic Roundup

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 30, 2026.

Emerging therapeutic strategies for Parkinson’s at ADPD 2026

BioWorld

Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...

Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques

Small-molecule TREM2 agonist advances to treat Alzheimer’s

BioWorld Science

Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...

With improved technologies, biomarkers, failed drugs may come into their own

BioWorld

At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 24, 2026